Workflow
Globenewswire
icon
搜索文档
ITGR LAWSUIT: Did Integer Holdings Corporation Mislead Investors? Contact BFA Law by February 9 Legal Deadline if You Suffered Losses
Globenewswire· 2025-12-29 14:07
NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Integer, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/int ...
JEF INVESTIGATION: Did Jefferies Financial Group Inc. Mislead Investors? Contact BFA Law about its Ongoing Securities Fraud Investigation if You Suffered Losses
Globenewswire· 2025-12-29 14:07
NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Leading international securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Jefferies Financial Group Inc. (NYSE: JEF) and Point Bonita Capital for potential violations of the federal securities laws after SEC probe is revealed. If you invested in Jefferies or Point Bonita, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/jefferies-financial-group-inc-class-action. Why are Jefferies and Point Bo ...
SNPS DEADLINE TOMORROW: Did Synopsys, Inc. Mislead Investors? Contact BFA Law by Tomorrow's December 30 Legal Deadline if You Suffered Losses
Globenewswire· 2025-12-29 14:07
NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Synopsys, Inc. (NASDAQ: SNPS) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Synopsys, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/synopsys-inc-c ...
Agreement Signed on Gas Transit to Kaliningrad
Globenewswire· 2025-12-29 14:07
协议核心条款 - 立陶宛天然气输运系统运营商Amber Grid签署了一份通过立陶宛共和国至加里宁格勒地区的天然气运输协议 [1] - 协议期限为五年,至2030年12月31日止 [1] - 服务价格由立陶宛国家能源监管委员会确定,其中2026年的许可收入水平设定为约3000万欧元 [1] 运营与技术细节 - 在合同期内,通往加里宁格勒地区的出口点每日可使用容量为1050万立方米 [2] - 根据立陶宛共和国《天然气法》规定,商业天然气交易将继续被禁止 [2] - 输运过程实行严格计量,注入管道的天然气总量需与在出口点释放的总量完全一致 [2] 监管与法律框架 - 此次天然气过境运输是基于国际协议和欧盟法规组织进行的 [1]
KMX LAWSUIT: Did CarMax, Inc. Mislead Investors? Contact BFA Law by January 2 Legal Deadline if You Suffered Losses
Globenewswire· 2025-12-29 14:07
NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against CarMax, Inc. (NYSE: KMX) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in CarMax, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/carmax-inc-class-acti ...
LRN LAWSUIT: Did Stride, Inc. Mislead Investors? Contact BFA Law by January 12 Legal Deadline if You Suffered Losses
Globenewswire· 2025-12-29 14:07
NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Stride, Inc. (NYSE: LRN) and certain of the Company’s senior executives for securities fraud after significant stock drops resulting from the potential violations of the federal securities laws. If you invested in Stride, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/stride-inc-class-actio ...
NASDAQ: SKYE INVESTOR ALERT: Berger Montague Advises Skye Bioscience, Inc. (NASDAQ: SKYE) Investors of a January 16, 2026 Deadline
Globenewswire· 2025-12-29 14:06
集体诉讼事件概述 - 一家名为Berger Montague PC的全国性原告律师事务所宣布,已代表在2024年11月4日至2025年10月3日期间购买或获得Skye Bioscience公司证券的投资者,对该公司提起集体诉讼 [1] 公司背景与指控核心 - Skye Bioscience总部位于圣地亚哥,是一家临床阶段的生物技术公司,专注于开发治疗肥胖和代谢疾病的疗法 [2] - 起诉书指控,在整个集体诉讼期间,公司管理层就其主打候选药物nimacimab的前景误导了投资者 [2] 关键负面事件与市场反应 - 投资者于2025年10月6日获悉真相,当日Skye公布了其nimacimab为期26周的2a期CBeyond试验的顶线结果,显示该药物未能达到相对于安慰剂的主要减重终点 [3] - 此消息导致Skye股价当日下跌2.85美元,跌幅约60%,收盘报1.90美元 [3] 原告律所信息 - Berger Montague是一家专注于复杂民事诉讼、集体诉讼和大规模侵权案件的知名律所,2025年仅审后判决金额就超过24亿美元 [5] - 该律所拥有超过55年历史,已为客户及其代表的集体追回超过500亿美元 [5]
INSP LAWSUIT: Did Inspire Medical Systems, Inc. Mislead Investors? Contact BFA Law by January 5 Legal Deadline if You Suffered Losses
Globenewswire· 2025-12-29 14:05
NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/in ...
BRBR INVESTIGATION: Did BellRing Brands Mislead Investors? Contact BFA Law about its Ongoing Securities Fraud Investigation if You Suffered Losses
Globenewswire· 2025-12-29 14:03
调查事件概述 - 国际证券律师事务所Bleichmar Fonti & Auld LLP宣布对BellRing Brands Inc (NYSE: BRBR) 涉嫌违反联邦证券法的情况展开调查 [1] 公司业务与调查背景 - BellRing Brands 主营便捷营养产品 核心品牌包括提供即饮蛋白奶昔和蛋白粉的 Premier Protein 和 Dymatize [2] - 公司在相关期间声称 Premier Protein 的“家庭渗透率达到历史新高”且“需求保持强劲” 增长“在所有渠道都很强劲” 由“分销扩张、加速的销售流速和增量促销活动”驱动 [2] - 调查指出 公司相关期间的销售增长可能并非由可持续的终端消费者需求驱动 而是由几家关键零售商的临时性贸易库存囤积所推动 [2] 股价下跌与关键披露 - 2025年5月5日盘后 BellRing 披露自2023年第二季度起“几家关键零售商降低了其手头库存周数” 这将对其2025年第三季度增长构成阻力 公司同时宣布扩大促销以提振销售并“抵消零售商贸易库存水平在第三季度的减少” [3] - 此消息导致BellRing股价在2025年5月6日从5月5日的每股77.34美元下跌13.96美元至每股63.38美元 跌幅超过18% [3] - 2025年8月4日盘后 BellRing 宣布 Premier Protein 即饮奶昔的季度消费量令人失望 鉴于先前公布的零售商去库存 原本预期消费量会大幅超过出货量 但结果却与出货量“更为一致” [4] - 此消息导致BellRing股价在2025年8月5日从8月4日的每股53.64美元下跌17.46美元至每股36.18美元 跌幅近33% [4]
WORK Medical Technology Group LTD Subsidiary Obtains Manufacturing Approval for Its AI-Automated Blood Cell Morphology Analyzer
Globenewswire· 2025-12-29 14:00
Hangzhou, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that its subsidiary, Hunan Saitumofei Co., Ltd., has received manufacturing approval from the Hunan Provincial Medical Products Administration for its Class II medical device, the Artificial Intelligence (“AI”)-Au ...